NR1H4

Bile acid receptor · Q96RI1 · NR1H4 on Sugi Atlas →

226,717 patent compounds predicted against NR1H4, 144,591 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Tebufenpyrad (SCHEMBL26848)	0.48	11/20
SCHEMBL11954	0.59	10/20
Squalamine (SCHEMBL12836)	0.53	8/20
SCHEMBL11774	0.48	8/20
Chenodiol (SCHEMBL25055)	1.00	7/20
Chenodiol (SCHEMBL25056)	1.00	7/20
Ursodiol (SCHEMBL27200)	1.00	7/20
Chenodiol (SCHEMBL27201)	1.00	7/20
Chenodiol (SCHEMBL61536)	0.98	7/20
SCHEMBL102305	0.51	7/20
Taurochenodeoxycholate (SCHEMBL40763)	1.00	6/20
Taurursodiol (SCHEMBL40764)	1.00	6/20
Taurochenodeoxycholate (SCHEMBL56779)	1.00	6/20
Taurochenodeoxycholate (SCHEMBL56780)	1.00	6/20
Glycoursodeoxycholic Acid (SCHEMBL59881)	1.00	6/20
Glycoursodeoxycholic Acid (SCHEMBL61042)	0.83	6/20
SCHEMBL14439	0.47	6/20
SCHEMBL75504	0.43	6/20
SCHEMBL75503	0.41	6/20
Taurochenodeoxycholate (SCHEMBL60947)	0.84	5/20

Clinical trials — most relevant to NR1H4 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Effect of the Sequestrant Colesevelam in Bile Acid Diarrhoea	PHASE4	COMPLETED
The Role of CYP8B1 Polymorphisms in Modulating the Biochemical Pathways Affected by SGLT2 Inhibitors in T2DM and Obesity	PHASE4	COMPLETED
Treatment of Bile Acid Diarrhoea With Atorvastatin	PHASE4	RECRUITING
Study of Ezetimibe for Chronic Hepatitis C Virus (HCV) Infection in Liver Transplant Candidates (EZE-2)	PHASE4	UNKNOWN
Obeticholic Acid Among Chronic HBV Patients with Hepatic Steatosis : Clinical and Portal Doppler Outcomes	PHASE3	NOT_YET_RECRUITING
BSEP Function Rescue During Childhood Inhereditary Cholestatic Diseases	PHASE2/PHASE3	WITHDRAWN
Fibrates in Pediatric Cholestasis	PHASE2	COMPLETED
Comparative Study Between Obeticholic Acid Versus Vitamin E in Patients with Non-alcoholic Steatohepatitis	PHASE2	ACTIVE_NOT_RECRUITING
Cholic Acid for Hepatic Steatosis in Lipodystrophy	PHASE2	COMPLETED
Obeticholic Acid in Bile Acid Diarrhoea	PHASE2	COMPLETED
Atorvastatin, L-Carnitine and Non-Alcoholic Steatohepatitis	PHASE2	UNKNOWN
Efficacy and Tolerability of Tauroursodeoxycholic Acid in Amyotrophic Lateral Sclerosis	PHASE2	COMPLETED
PiCCA Study (Panitumumab in Combination With Cisplatin/Gemcitabine)	PHASE2	COMPLETED
Drug Interaction and Food Effect Study of CS0159	PHASE1	COMPLETED
Ursodiol, Combination Chemotherapy, and Bevacizumab in Treating Patients With Stage IV Colorectal Cancer	PHASE1	COMPLETED
Effect of Obeticholic Acid on Transport of Bile Acids in PBC Examined by 11C-cholyl-sarcosine PET/CT	EARLY_PHASE1	COMPLETED
The Metabolic Profile in Intrahepatic Cholestasis of Pregnancy and Diabetes Mellitus	nan	COMPLETED
Role of Obeticholic Acid in the Patients of NAFLD With Raised ALT	nan	COMPLETED
The Effect of Sleeve Gastrectomy on Post-prandial Serum Bile Acids	nan	COMPLETED
FGF19 in Obstructive Cholestasis: Unveil the Signal	nan	UNKNOWN
Effects of Colesevelam HCl On Bile Acid Kinetics	nan	COMPLETED
The Effect of Dietary Lauric Acid on the Production of the LRH-1 Ligand, Dilauroylphosphatidylcholine	nan	COMPLETED
The Microbiome Composition in Women With Recurring Intrahepatic Cholestasis of Pregnancy (ICP)	nan	COMPLETED
The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease.	nan	RECRUITING
Remedial Mechanism of Simvastatin and Ursodeoxycholic Acid in Liver Cirrhosis: Crosstalk of Bile Secretion, Gut Microbiome, and Host Immune Response	nan	ENROLLING_BY_INVITATION
Mechanisms of Glucose Lowering Effect of Colesevelam HCl	nan	COMPLETED
Osmotic Fragility in Red Blood Cells of Pediatric Patients With Cholestatic Liver Disease	nan	ACTIVE_NOT_RECRUITING
Study of Changes in Total Cholesterol Levels as a Function of Consuming a Supplement Designed to Improve Cardiovascular Health	nan	UNKNOWN
Gut Microbiota and Modulation of Liver Damage in NAFLD	nan	COMPLETED
Utilizing Non-Invasive Fibroscan® Technology to Identify Genetic Markers for Fatty Liver Progression	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a NR1H4 binder may also engage these)

Protein	Name	Similarity
Q3SZL0	—	1.000	Q3SZL0 →
Q62735	—	1.000	Q62735 →
Q60641	—	1.000	Q60641 →
Q9XSB5	—	0.994	Q9XSB5 →
P51448	—	0.994	P51448 →
A0JNE3	—	0.993	A0JNE3 →
F1QLY4	—	0.993	F1QLY4 →
Q9XSW2	—	0.993	Q9XSW2 →
Q9TU15	—	0.993	Q9TU15 →
Q8VIJ4	—	0.992	Q8VIJ4 →
Q9R1A7	—	0.991	Q9R1A7 →
Q0ZAQ8	—	0.991	Q0ZAQ8 →
Q9W6M2	—	0.991	Q9W6M2 →
Q64249	—	0.991	Q64249 →
Q9PVE2	—	0.991	Q9PVE2 →
Q6GN21	—	0.991	Q6GN21 →
O35507	—	0.991	O35507 →
P57782	—	0.991	P57782 →
P49701	—	0.990	P49701 →
P06212	—	0.990	P06212 →
THRA	Thyroid hormone receptor alpha	0.990	landscape →
RORA	Nuclear receptor ROR-alpha	0.990	landscape →
P06211	—	0.990	P06211 →
P37242	—	0.990	P37242 →
P03373	—	0.990	P03373 →
O54915	—	0.990	O54915 →
Q63504	—	0.990	Q63504 →
Q60674	—	0.990	Q60674 →
Q9PTU5	—	0.990	Q9PTU5 →
Q95171	—	0.990	Q95171 →